Podcasts about Torque

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Aubrey converses with Blaque Nubon, a podcaster, musician, husband, father and host of The Husband Podcast, about how fatherhood, manhood, and emotional wellbeing shape the homes we build and the men we become. Blaque Nubon challenges men to rethink what it means to be present, to lead with purpose, and to break generational cycles. The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Welcome to the Celestial Insights Podcast, the show that brings the stars down to Earth! Each week, astrologer, coach, and intuitive Celeste Brooks of Astrology by Celeste will be your guide. Her website is astrologybyceleste.com.  

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In Episode 249 of The Rainmaking Podcast, Scott Love welcomes back productivity strategist and international speaker Sarah Tetlow to discuss the power of effective delegation for rainmakers. Sarah introduces her TORQUE model—Trust, Organized, Repetition, Quality, Understanding, and Eliminate control—as a strategic framework for lawyers and professionals looking to delegate more effectively and free up time for high-value rainmaking activities. She emphasizes that mutual trust and respect between delegator and delegate are foundational, and that anticipating workflow and planning ahead—even with just 15–30 minutes daily—can unlock time and resources for better outcomes. Through practical advice and relatable anecdotes, Sarah shows how thoughtful delegation leads to improved team performance and personal productivity. Sarah also highlights the psychological roadblocks to delegation—especially perfectionism and control—and shares actionable insights for overcoming them. She encourages professionals to invest in their team, create repeatable processes, and embrace the reality that 80% of someone else's effort, if done consistently, can exceed the output of going it alone. The episode concludes with Sarah offering a free delegation toolkit on her site, helping listeners take immediate action to implement TORQUE in their own practices. Visit: https://therainmakingpodcast.com/ YouTube: https://youtu.be/ZFL7TX2NAjE ----------------------------------------

Faut-il interdire certains livres dans nos écoles ? Discussion avec Rémi Villemure, chroniqueur Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radio Pour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

In this episode of Air Power Airwaves we bring back Sam from GCI Engineered Solutions to discuss the ways his magnificent team can help our customers of the fastening side of manufacturing!!Host Travis Stirewalt welcomes back Sam Goebel, the General Manager of GCI Engineered Solutions, for a chat about how they can help improve the safety, efficiency and precision of a manufacturing process. Aaron Osbourne, Air Power Application Engineer, joins the discussion to breakdown..... - Torque Reaction - how GCI helps protect your operators from the dangers of high torque fastening - Tool Tip Tracking - making sure those bolts are being fastened properly gets easier thanks to GCI - Multi Spindles - The use, flexibility and benefits of using multi spindles in your process - Some specific examples of Air Power and GCI's partnership over the yearsIf you have any questions about today's topic or would like to schedule an Air Power visit to your facility for more information on GCI's Engineered Solutions please contact Air Power today at 1-800-334-1001.Connect with Air Power Manufacturing Solutions on: LinkedIn | Facebook | Instagram | Twitter

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

We're diving deep into the world of zero-torque putters — the techy flatsticks designed to stay square and keep your stroke stable. After tons of testing, we're ranking our Top 10 Zero-Torque Putters of the year! From full-on futuristic to surprisingly traditional, these are the ones that actually perform on the greens.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Andy Edstrom unpacks whether Bitcoin is truly the last asymmetric bet for companies, diving into MicroStrategy's model, capital structure risks, and Bitcoin's rising institutional role. IN THIS EPISODE YOU'LL LEARN: 00:00 - Intro 03:40 - Why Michael Saylor calls Bitcoin a lifeline for “zombie companies” 05:20 - How Bitcoin's returns compare to traditional assets over the last decade 07:10 - The strategic and accounting evolution enabling Bitcoin treasury allocations 12:00 - MicroStrategy's premium-to-NAV strategy and its replicability 15:40 - Risks and rewards of BTC-backed leverage and convertible notes 18:05 - The logic behind “torque” metrics in Bitcoin-financed capital structures 21:10 - If preferred shares like STRK and STRF are innovative or dangerous 23:05 - Wall Street's changing views on Bitcoin-leveraged equity plays 27:20 - Legal and governance hurdles in corporate Bitcoin adoption 29:10 - What a BTC-heavy balance sheet should do during a major drawdown Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Andy's X Account. Microstrategy Shareholders' Meeting: Q1 2025 Earnings Call. Michael Saylor's speech at Strategy World: Bitcoin for Corporations 2025 Keynote Speech. Check out all the books mentioned and discussed in our podcast episodes ⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠. Enjoy ad-free episodes when you subscribe to our ⁠⁠⁠⁠⁠⁠Premium Feed⁠⁠⁠⁠⁠⁠. NEW TO THE SHOW? Join the exclusive ⁠⁠⁠TIP Mastermind Community⁠⁠⁠ to engage in meaningful stock investing discussions with Stig, Clay, Kyle, and the other community members. Follow our official social media accounts: ⁠⁠⁠X (Twitter)⁠⁠⁠ | ⁠⁠⁠LinkedIn⁠⁠⁠ | | ⁠⁠⁠Instagram⁠⁠⁠ | ⁠⁠⁠Facebook⁠⁠⁠ | ⁠⁠⁠TikTok⁠⁠⁠. Check out our ⁠⁠⁠Bitcoin Fundamentals Starter Packs⁠⁠⁠. Browse through all our episodes (complete with transcripts) ⁠⁠⁠here⁠⁠⁠. Try our tool for picking stock winners and managing our portfolios: ⁠⁠⁠TIP Finance Tool⁠⁠⁠. Enjoy exclusive perks from our ⁠⁠⁠favorite Apps and Services⁠⁠⁠. Get smarter about valuing businesses in just a few minutes each week through our newsletter, ⁠⁠⁠The Intrinsic Value Newsletter⁠⁠⁠. Learn how to better start, manage, and grow your business with the ⁠⁠⁠best business podcasts⁠⁠⁠. SPONSORS Support our free podcast by supporting our ⁠⁠⁠sponsors⁠⁠⁠: SimpleMining Hardblock AnchorWatch Fundrise DeleteMe CFI Education Vanta The Bitcoin Way Onramp Indeed Shopify HELP US OUT! Help us reach new listeners by leaving us a ⁠⁠⁠rating and review⁠⁠⁠ on ⁠⁠⁠Spotify⁠⁠⁠! It takes less than 30 seconds, and really helps our show grow, which allows us to bring on even better guests for you all! Thank you – we really appreciate it! Support our show by becoming a premium member! https://premium.theinvestorspodcast.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm

Geoff Mangum (IG: @geoffmangum, FB: @geoff.mangum, YT: @geoffmangum) is the world leader when it comes to all things putting. He has spent more than 35 years reading and researching anything and everything that has to do with putting. In this episode, Geoff delves into the intricacies of putting, critiquing various theories and methods, particularly the Aim Point system. He also discusses the limitations of human perception in reading slopes, the importance of instinctive learning in golf, and the effectiveness of distance control techniques. This episode also touches on the zero-torque putter phenomenon, emphasizing the need for golfers to understand the physics behind their equipment and techniques rather than relying on gimmicks. If you would like to read Geoff's book ‘Optimal Putting: Brain, Science, Instincts, and the Four Skills of Putting' you can get it HERE. Affiliates: PAYNTR Golf Shoes - Payntr Golf delivers performance traction resulting from our shoe's ability to resist, support, & enhance – allowing golfers the capacity to leverage ground forces, control movement, and maximize speed at impact. https://payntrgolf.com/golf360 Books by Rande Somma Why Do We Call Them Leaders?: https://amzn.to/3VIhDI6 Leadersh!t: https://amzn.to/3VY4zib The Stack System is the ultimate device to use when looking to biohack your swing speed. Co-developed by ‘The Savant of Speed' – Dr. Sasho MacKenzie, and PING engineer Marty Jertsen, it is a device that every golfer can utilize to increase their swing speed. The Stack System uses AI to ensure that your development is as efficient as possible. To order The Stack you can do so on their website at www.thestacksystem.com. Be sure to use the discount code GOLF360 to receive your special discount. Sponsors: Get your 15% discount on your next order of JustThrive Probiotic at https://justthrivehealth.com/ (use code: GOLF360) Looking to play one of the best golf courses in the Hilton Head Island area? Be sure to check out Old South Golf Links and have one of your best golf experiences ever https://www.oldsouthgolf.com/  

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode, I dive deep into the Dan Carraher Zero Torque Putter — a unique design built for maximum stability and consistency. From the feel at impact to performance on the green, I break down everything you need to know about this putter's performance, looks, and tech. Is this the future of putting? Let's find out.  

We're back with a monster episode — LIVE (well, filmed live) from the buzzing ELEX Show at Alexandra Palace!Episode 18 of the Torque Up Podcast brings you a full mix of laughs, honesty, trade talk, and behind-the-scenes realities from some of the biggest personalities in the industry.Featuring: • Tall Sparky & Ryan Davis – raw takes on content burnout, chasing dream lives, and what people don't see behind the posts • OM Electrical – from bored spark to content beast, saying no to brands, and why filming a consumer unit isn't always worth it • Charlie from Wiha UK – tools, backpacks, and his first-ever trade show experience • Julian & Elliot from Chauvin-Arnoux – banter, testing talk, and rescuing pigs during a year off • Plus reflections on social media pressure, holiday cover systems, and the truth about making content in the tradeThis episode is a proper celebration of trade creators, community, and graft — filmed in the middle of the busiest tool show in the UK.AND this is just the beginning. Torque Up will be at EVERY ELEX SHOW for the rest of the year.Come find us, jump on the mic, and be part of the movement.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Key topics in today's conversation include:Bruce Background and Journey (1:11)Importance of Early Exposure to Trucking (5:05)Owner-Operators and Their Resilience (6:05)The Appeal of Trucking (8:52)Community Support Among Truckers (10:32)Performance of Various Engines (13:14)Bruce's Personal Retirement Reflections (15:12)Listening to Customer Needs (20:43)Hurricane Helene Damage (27:51)Retirement Realities (38:01)The Addiction to Trucking (42:36)Retirement for Owner-Operators (43:39)The Supply Chain and Trucking (48:09)Trucker Appreciation (49:44)Final Thoughts and Takeaways (51:45)Oakley Trucking is a family-owned and operated trucking company headquartered in North Little Rock, Arkansas. For more information, check out our show website: podcast.bruceoakley.com.

Thoughts on the Teeter Totter of Cadence and Torque - Ep 164 Most often, riders associate making power with pushing harder on the pedals. The sensation of the bottom of the shoe providing resistance against the plantar surface [bottom] of the foot is how the sensation of “going hard” is processed.  However, speed on a bicycle is dictated by the complex interaction of weather [including wind, temperature, pressure and humidity], terrain, inertia, riding surface, and the output of the rider. Output = power, and power is comprised of two components: torque and cadence.  Thus, in certain conditions, it is advantageous to be able to make power by pedaling faster, not only by pedaling harder. If your only strategy to make more power is pushing harder on the pedals, at the expense of any capacity for triple digit cadence, your abilities as a rider will be limited. 

Insert Content Template or Symbol Zero Torque Putters!David Orr Interview Welcome to Episode 223 of THE Golf Improvement Podcast!  Dedicated to sharing useful information on professional club fitting, putting and short game improvement, and effective practice techniques. CHANGING GOLFER'S LIVES - ONE GOLFER AT A TIME! Show Notes:Welcome back - for the 9th time! - David…

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Little did we know when we recorded this episode at the end of March that we'd be sitting here right now with Rory McIlroy as a Grand Slam winner. Yes, we filmed this many weeks before the Masters, so we are clueless to Rory's triumph, hence the complete lack of reference to one of the biggest moments in our sport's history!  Back to matters of equipment. This week, Dan has a rant about driving range etiquette and people's obsession with how far they're hitting the ball, Joe has an explainer all about torque in shafts, and this week's Ask The Pod wants to know what our dream equipment and apparel sponsors would be. Later, we're joined by Northern Ireland's second-best golfer (sorry, Tom), gear nerd and equipment aficionado Tom McKibbin, for an in-depth look into his bag for the 2025 season.  Get in touch with Dan and Joe and 'Ask The Pod' via our email: kickpointpodcast@futurenet.com Sign up for the weekly Kick Point newsletter, released every Friday: https://www.golfmonthly.com/newsletter  Get three issues of the Golf Monthly magazine delivered to your door for just £5 at https://www.magazinesdirect.com/kickpoint    Watch us in full on YouTube: https://www.youtube.com/@KickPointGolf Chapters: 0:00:00 Hello! 0:04:05 Joe was on No Laying Up (sort of) 0:09:05 A driving range rant - stop worrying about yardage!  0:22:53 What is torque in shafts? 0:42:06 Ask The Pod - what equipment brand would we like to be sponsored by? 0:54:29 Tom McKibbin What's In The Bag special! 

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode, Paul was asked a question about torquing and his thoughts on torque values and the changes from calibrated torque tools to now approved method. Paul also answers a question about SER being stripped out for use in raceways.Listen as Paul Abernathy, CEO, and Founder of Electrical Code Academy, Inc., the leading electrical educator in the country, discusses electrical code, electrical trade, and electrical business-related topics to help electricians maximize their knowledge and industry investment.If you are looking to learn more about the National Electrical Code, for electrical exam preparation, or to better your knowledge of the NEC then visit https://fasttraxsystem.com for all the electrical code training you will ever need by the leading electrical educator in the country with the best NEC learning program on the planet.Become a supporter of this podcast: https://www.spreaker.com/podcast/master-the-nec-podcast--1083733/support.

In this episode, Paul was asked a question about torquing and his thoughts on torque values and the changes from calibrated torque tools to now approved method. Paul also answers a question about SER being stripped out for use in raceways.Listen as Paul Abernathy, CEO, and Founder of Electrical Code Academy, Inc., the leading electrical educator in the country, discusses electrical code, electrical trade, and electrical business-related topics to help electricians maximize their knowledge and industry investment.If you are looking to learn more about the National Electrical Code, for electrical exam preparation, or to better your knowledge of the NEC then visit https://fasttraxsystem.com for all the electrical code training you will ever need by the leading electrical educator in the country with the best NEC learning program on the planet.Become a supporter of this podcast: https://www.spreaker.com/podcast/ask-paul-national-electrical-code--4971115/support.

(00:00:34) "Le ciel ne va pas s'écrouler" rétorque Pékin face aux droits de douane américains (00:05:14) Série "Le Japon veut montrer la voie" (épisode 3): la maîtrise de la technologie au quotidien (00:13:57) Comment les écoles espagnoles enseignent le franquisme 50 ans après la mort de Franco

In this episode, Paul was asked a question about torquing and his thoughts on torque values and the changes from calibrated torque tools to now approved method. Paul also answers a question about SER being stripped out for use in raceways.Listen as Paul Abernathy, CEO, and Founder of Electrical Code Academy, Inc., the leading electrical educator in the country, discusses electrical code, electrical trade, and electrical business-related topics to help electricians maximize their knowledge and industry investment.If you are looking to learn more about the National Electrical Code, for electrical exam preparation, or to better your knowledge of the NEC then visit https://fasttraxsystem.com for all the electrical code training you will ever need by the leading electrical educator in the country with the best NEC learning program on the planet.Become a supporter of this podcast: https://www.spreaker.com/podcast/ask-paul-national-electrical-code--4971115/support.

Aubrey speaks to Mbuyiselo Botha, Gender Activist and Founder of SA’s Men’s Forum, about what does it mean to be a an in this present day.See omnystudio.com/listener for privacy information.

Ray finds the storage limit of his FJ Cruiser while Chris finds missing lug nut caps.  Torque wrenches, torque sticks & lug wrenches get questioned, as does the proper use of friction straps. Headlight upgrades lead into a classic editorial written by Joe Oldham of Cars magazine.  A caller ruminates with Ray over changing an Ecotec valve cover. Check our social media feed to see the pictures; on Instagram: @real_motormouthradio and on You Tube: https://youtu.be/B2unIs0H2N4

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this conversation, Grant Holicky discusses the challenges and dynamics of life changes, particularly in relation to his family and home situation. He transitions into the specifics of cyclocross training, emphasizing the unique demands of the discipline, including the need for varied energy systems and strength training. The importance of off-bike training, including running and strength work, is highlighted as essential for cyclists. The discussion also covers endurance training guidelines, the significance of individualization in training plans, and the need for athletes to adapt their training to their personal circumstances and goals.Thanks, Grant! Find him on IG here: https://www.instagram.com/gholicky/Chapters:00:00 The Mindset of "Good Legs": An Introduction to Grant Holicky01:22 Cyclocross Training: Intensity, Torque, and Terrain04:26 Strength and Skill: Building a Well-Rounded Cyclist08:48 Developing Young Riders: The Benefits of Cyclocross10:50 Strength Training: Mobility, Stability, and Longevity16:16 Endurance Training: Beyond the Data, Listening to Your Body23:52 Individualized Training: Breaking Free from World Tour Models33:23 The Athlete-Coach Partnership: Communication and Adaptation40:28 Mental Strength: Cultivating Resilience and Optimal Performance57:09 Recovery, Bro Science, and the Future of Cycling TrainingJoin this channel to get access to videos a month early! And it directly supports the channel so we can bring you more content!https://www.youtube.com/channel/UCS9FDuHl_qp8ajqQuWwNtew/join

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

If you're a bit of a putter nerd or a total putter newbie, then you're in luck this week as our guru Sam De'Ath returns to give us the full lowdown on the latest craze in flatstick technology - zero torque putters! Unfortunately, that means no Joe this week. Eagle-eyed viewers will notice he had a bit of tape on the sole of his shoe all last week, and I would like to say he's sitting out this week out of embarrassment, but that would be lying... Instead, this episode was supposed to air last week, but one of the products we spoke about was embargoed, and we can't be upsetting the friendly companies that supply us with these clubs to test, can we? However, we promise that this episode is worth the wait. We cover zero torque - what they are, why you might use one and which ones we think are the best depending on what kind of golfer you are.  Get in touch with Dan and Joe and 'Ask The Pod' via our email: kickpointpodcast@futurenet.com Sign up for the weekly Kick Point newsletter, released every Friday: https://www.golfmonthly.com/newsletter  Get three issues of the Golf Monthly magazine delivered to your door for just £5 at https://www.magazinesdirect.com/kickpoint    Watch us in full on YouTube: https://www.youtube.com/@KickPointGolf Follow us on social media: Instagram -  https://www.instagram.com/kickpointgolf TikTok - https://www.tiktok.com/@kickpointpod Chapters: 0:00:00 Intro  0:06:23 What is a 'zero-torque putter'? 0:10:23 Is L.A.B Golf here to stay? 0:14:43 What are all the models? 0:16:55 Best looking zero-torque putter 0:29:34 Best feeling zero-torque putter 0:39:29 Best for alignment 0:46:41 Best inside 5ft 0:50:59 Best overall zero torque putter 0:57:28 'Ask The Pod' - Building the top and bottom of a bag

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

For today's podcast, we're joined by Josh Lewis and Jamie Miller from Sleazoids to talk about Joseph Kahn's 2004 Mtn Dew motorcycle action movie, Torque. There is a whole lot of style, absurdity, and Bush-era bad taste to get into in this feature debut from one of the music video kings. Get an extra episode every week for $5/mo at https://www.patreon.com/c/Extended_Clip Email us at extendedclippodcast@gmail.com with your questions to be answered on the podcast. Listen to SLEAZOIDS

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Aubrey speaks with Dr Tawanda Makusha, co-editor of the report and senior research associate at the Africa Health Research Institute (AHRI), to unpack some of the findings of the State of South African Fathers Report. See omnystudio.com/listener for privacy information.

Do you like cars, man? What about trucks? 

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Torque is the force that keeps a system stable and in motion—just like cybersecurity, where constant pressure, precision, and adaptability are critical to staying ahead of threats. Curt Vincent knows this well, having transitioned from troubleshooting turbine engines in the Army to leading cybersecurity at the highest levels of Wall Street. A retired U.S. Army Lieutenant Colonel with tech-heavy deployments in Desert Storm and post-9/11 cyber warfare, Curt went on to build and lead Morgan Stanley's 400-person Cyber Security Division, later holding executive roles at Bank of America and Goldman Sachs. Now a trusted advisor to C-suites and boards, Curt shares how the lessons of engineering, military strategy, and high-stakes cyber defense all come down to maintaining control under pressure.TIMESTAMPS:00:00 Curt Vincent's Journey to Cybersecurity14:40 Building Cybersecurity at Morgan Stanley28:39 Cultural Shifts in Cybersecurity Practices29:24 The Disconnect Between Cybersecurity and Business32:13 Accountability and Consequences in Cybersecurity35:12 Communication and Leadership in Cybersecurity38:40 Connecting with the Audience: The Role of Analogies39:14 Unique Experiences and Cultural PerspectivesSYMLINKS:Curt Vincent's Website - https://curtvincent.comCurt Vincent's speaker website where he shares insights on cybersecurity, leadership, and consulting.KnowBe4 - https://www.knowbe4.comA cybersecurity awareness training platform that specializes in phishing simulation and security education to help organizations mitigate human-related risks.Proofpoint - https://www.proofpoint.comA cybersecurity company providing threat intelligence, email security, and phishing prevention solutions to protect organizations from cyber threats.Morgan Stanley Cybersecurity - https://www.morganstanley.com/Morgan Stanley's approach to cybersecurity includes best practices and risk management strategies for businesses and individuals.Widener University - https://www.widener.eduThe university where Curt Vincent pursued his degree before re-entering the military and advancing in his cybersecurity career.CONNECT WITH USwww.barcodesecurity.comBecome a SponsorFollow us on LinkedInTweet us at @BarCodeSecurityEmail us at info@barcodesecurity.com

Plaza Colonia y Defensor Sporting son los únicos líderes del Torneo Apertura del fútbol uruguayo, disputada la segunda fecha.  Ambos equipos tienen puntaje perfecto.  Con cuatro puntos está Peñarol, luego de su empate de ayer 1-1 con Nacional. También con cuatro puntos están Cerro Largo, Cerro, Liverpool y Torque.  Con dos puntos aparecen Danubio y Juventud, y con uno está Nacional, junto a River, Racing, Boston River y Wanderers.  Sin puntos y en fondo de la tabla del Apertura están Miramar Misiones y Progreso.  Conversamos En Perspectiva con Sebastián Moreira, del equipo de Por Decir Algo.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode, we sit down with Derek "Torque" McMaster as he shares his raw and inspiring journey from battling addiction to becoming a leader, mentor, and man of faith. Derek's story is a testament to the power of second chances, the importance of surrounding yourself with strong influences, and the undeniable grace of God. If you or someone you love is struggling, this episode is proof that you don't have to stay where you are—change is possible.

Follow Joaquin here: https://livgolfleague.tv/joaco_niemann-igFollow Torque: https://livgolfleague.tv/torqueSubscribe to Torque: https://livgolfleague.tv/TORQUE-YT Hosted on Acast. See acast.com/privacy for more information.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Each Friday, we post a featured Question of the Week on the ThisIsBracketRacing Facebook page. This week, we're giving YOU, the Daily Driver listener an early look, releasing the Question of the Week here two days in advance! For this week's question, we reached out to ThisIsBracketRacing ELITE instructor (and our resident tech expert), Justin Lamb. The question: "How do I select the best torque converter for my application?"

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

The folks at L.A.B. Golf believe that most golfers are using putters that aren't helping them putt better. In fact, they believe that their putter styles are working against them. Sam Hahn, the founder of L.A.B. Golf joins #OntheMark to talk with Mark Immelman about the L.A.B. Golf putters and how their Lie Angle Balance technology can help golfers improve their putting strokes and make more putts. Hahn introduces the selection of L.A.B. putters and the PGA TOUR player that have changed their putting fortunes by using them.  He also talks about: The hallmark of great putting - returning the putter face to “square” at impact, or perpendicular to the target line and how LAB putters make that easier. The research showing that 83% of a putt's starting direction is influenced by the direction of the putter face at impact. What is Lie Angle Balance Technology and the design of LAB putters with elements like Weighting, Shaft design and angle, Grip alignment and style. The influence of Torque in the putting stroke, and on the putter face, and the elements in the LAB putters that reduce torque for more control. "Torque Hangover" in putting and grip pressure for putter face control. How Lie Angle Balance (L.A.B.) Technology makes it effortless for golfers to deliver a square putter face at impact. How Lie Angle Balance allows a golfer to make a natural stroke with less mechanical effort to keep maintain an accurate Swing Path. Improving your putting is the easiest way to lower your scores.  Download and listen as Sam Hahn illustrates how his L.A.B. putters can help you to make better, more consistent, more reliable putting strokes - strokes that will lead to more holed putts. This podcast is also available as a vodcast on YouTube - search and subscribe to Mark Immelman.